MRI路径与TRUS活检在初诊PSA升高男性中的头对头比较
这项前瞻性多中心研究纳入626例未活检且PSA≥3ng/ml的男性,比较MRI路径(mpMRI后MRGB)与TRUSGB路径。MRI路径csPCa检出率25% vs TRUSGB 23%(差异无统计学意义),但insignPCa显著减少(14% vs 25%),且49%患者避免活检,仅4%在1年随访时检出csPCa。
要点
- MRI路径与TRUSGB对csPCa检出率相当,但显著减少无临床意义癌检出。
- 49%患者因mpMRI无 suspicious 病灶而避免活检,1年随访仅4%检出csPCa。
- MRI路径使活检针数减少89%(从7512降至849)。
核心结论
- 在未活检男性中,MRI路径与TRUSGB路径对csPCa的检出率相同,但MRI路径显著减少insignPCa病例。
- 不进行TRUS活检的代价是仅4%的csPCa在1年随访时被检出。
研究设计与样本
- 前瞻性、多中心、效能验证的比较效果研究,纳入626例未活检且PSA≥3ng/ml的患者(2015年2月至2018年2月)。
- 所有患者先行mpMRI,随后行系统TRUSGB;mpMRI有可疑病灶者先行MRGB(in-bore方法)再行TRUSGB。
主要发现
- MRI路径检出csPCa 159/626(25%),insignPCa 88/626(14%);TRUSGB检出csPCa 146/626(23%),insignPCa 155/626(25%)。
- MRI路径 vs TRUSGB路径对csPCa的相对敏感性为1.09(p=0.17),对insignPCa为0.57(p<0.0001)。
- 活检总针数从7512降至849(-89%)。
- 309/626(49%)患者因mpMRI无 suspicious 病灶而避免活检,其中即刻TRUSGB检出csPCa仅3%(10/309),1年随访增至4%(13/309);TRUSGB过度检出insignPCa 20%(63/309)。
- 对MRGB增加4个病灶周围核心(「focal saturation」)使21/317(7%)患者csPCa检出改善。
关键数值与推荐
- csPCa定义为任何核心的grade group ≥2(Gleason评分≥3+4)。
- 本研究中mpMRI无 suspicious 的比例为49%,高于文献报道的27-36%;可疑病例比例为6%,低于文献的15-28%。
临床怎么用
- 对未活检且PSA≥3ng/ml的男性,可优先采用mpMRI路径,以减少不必要的活检和insignPCa检出。
- mpMRI无 suspicious 病灶者可避免立即活检,但需注意1年随访中约4%检出csPCa。
局限性
- 本研究中mpMRI无 suspicious 比例较高、可疑病例比例较低,可能源于高质量标准,结果在经验较少的中心难以复制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is growing interest to implement multiparametric magnetic resonance imaging (mpMRI) and MR-guided biopsy (MRGB) for biopsy-naïve men with suspected prostate cancer. OBJECTIVE: Primary objective was to compare and evaluate an MRI pathway and a transrectal ultrasound-guided biopsy (TRUSGB) pathway in biopsy-naïve men with prostate-specific antigen levels of ≥3ng/ml. DESIGN, SETTING, AND POPULATION: A prospective, multicenter, powered, comparative effectiveness study included 626 biopsy-naïve patients (from February 2015 to February 2018). INTERVENTION: All patients underwent prebiopsy mpMRI followed by systematic TRUSGB. Men with suspicious lesions on mpMRI also underwent MRGB prior to TRUSGB. MRGB was performed using the in-bore approach. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Clinically significant prostate cancer (csPCa) was defined as grade group ≥2 (Gleason score ≥3+4) in any core. The main secondary objectives were the number of men who could avoid biopsy after nonsuspicious mpMRI, the number of biopsy cores taken, and oncologic follow-up. Differences in proportions were tested using McNemar's test with adjusted Wald confidence intervals for differences of proportions with matched pairs. RESULTS AND LIMITATIONS: The MRI pathway detected csPCa in 159/626 (25%) patients and insignificant prostate cancer (insignPCa) in 88/626 patients (14%). TRUSGB detected csPCa in 146/626 patients (23%) and insignPCa in 155/626 patients (25%). Relative sensitivity of the MRI pathway versus the TRUSGB pathway was 1.09 for csPCa (p=0.17) and 0.57 for insignPCa (p<0.0001). The total number of biopsy cores reduced from 7512 to 849 (-89%). The MRI pathway enabled biopsy avoidance in 309/626 (49%) patients due to nonsuspicious mpMRI. Immediate TRUSGB detected csPCa in only 3% (10/309) of these patients, increasing to 4% (13/309) with 1-yr follow-up. At the same time, TRUSGB would overdetect insignPCa in 20% (63/309). "Focal saturation" by four additional perilesional cores to MRGB improved the detection of csPCa in 21/317 (7%) patients. Compared with the literature, our proportion of nonsuspicious mpMRI cases is significantly higher (27-36% vs 49%) and that of equivocal cases is lower (15-28% vs 6%). This is probably due to the high-quality standard in this study. Therefore, a limitation is the duplication of these results in less experienced centers. CONCLUSIONS: In biopsy-naïve men, the MRI pathway compared with the TRUSGB pathway results in an identical detection rate of csPCa, with significantly fewer insignPCa cases. In this high-quality standard study, almost half of men have nonsuspicious MRI, which is higher compared with other studies. Not performing TRUS biopsy is at the cost of missing csPCa only in 4%. PATIENT SUMMARY: We compared magnetic resonance imaging (MRI) with MRI-guided biopsy against standard transrectal ultrasound biopsy for the diagnosis of prostate cancer in biopsy-naïve men. Our results show that patients can benefit from MRI because biopsy may be omitted in half of men, and fewer indolent cancers are detected, without compromising the detection of harmful disease. Men also need fewer needles to make a diagnosis.
引用
- van der Leest M, Cornel E, Israël B, et al. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. Eur Urol. 2018. PMID: 30477981. doi:10.1016/j.eururo.2018.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。